Annual Secretarial Compliance Report for the FY 2024-25.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Oxygenta Pharmaceutical Ltd has submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2025, as required under Regulation 24A of SEBI LODR Regulations, 2015. The Practicing Company Secretary certified that the company is generally compliant with applicable SEBI regulations, secretarial standards, insider trading norms, and disclosure requirements, with no new deviations or penalties reported for FY 2024-25. The report also discloses a prior advisory letter from BSE dated April 23, 2024, regarding a timing mismatch in disclosing the appointment of the Company Secretary (the company had disclosed within 12 hours of the Board meeting rather than 12 hours of the actual appointment date), which the Board noted in its May 30, 2024 meeting. No actions were taken by SEBI or stock exchanges against the company during the year, and there were no subsidiary-related or auditor-resignation issues.
This is a routine annual compliance filing and largely housekeeping in nature, with no new penalties or material non-compliance for shareholders to worry about. The disclosure of the old BSE advisory letter is a carry-forward from FY 2023-24 and is not expected to impact the stock price.